Details About Generic Salt ::  Alosetro

Main Medicine Class:: 5HT3 receptor antagonist   

(al-OH-seh-trahn)

Lotronex

Tablets: 1.124 mg (equivalent to 1 mg alosetron base)

Class: 5HT3 receptor antagonist

 Indications Treatment of irritable bowel syndrome (IBS) in women whose predominant bowel syndrome is diarrhea.

Treatment of IBS in men; carcinoid diarrhea.

 Contraindications History of chronic or severe constipation or sequelae from constipation; history of intestinal obstruction, stricture, toxic megacolon, GI perforation, or adhesions; history of ischemic colitis; current or history of Crohn disease or ulcerative colitis; active diverticulitis. Do not initiate therapy in patients with constipation (fewer than 3 bowel movements a week, hard or lumpy stools, or straining during a bowel movement).

 Route/Dosage

ADULT: PO 1 mg/day initially. If after 4 wk the 1 mg/day dose is well tolerated but does not adequately control IBS symptoms, the dose can be increased to 1 mg bid.

 Interactions None well documented.

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Hypertension. CNS: Sleep disorders; depressive disorders. GI: Constipation; nausea; GI discomfort and pain; abdominal discomfort and pain; GI gaseous symptoms; viral GI infections; dyspeptic symptoms; abdominal distention; hemorrhoids. RESPIRATORY: Allergic rhinitis; throat and tonsil discomfort and pain; bacterial ear, nose and throat infections.

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk of lactating rats. CHILDREN: Safety and efficacy not established. ELDERLY: Safety was similar in older and younger patients. GI events: Serious complications of constipation and ischemic colitis may result in hospitalization, blood transfusion, surgery, and death. Hepatic impairment: Increased exposure to alosetron is likely to occur in patients with hepatic insufficiency; use with caution.

 

Drugs Class ::

(al-OH-seh-trahn)

Lotronex

Tablets: 1.124 mg (equivalent to 1 mg alosetron base)

Class: 5HT3 receptor antagonist

Indications for Drugs ::

 Indications Treatment of irritable bowel syndrome (IBS) in women whose predominant bowel syndrome is diarrhea.

Treatment of IBS in men; carcinoid diarrhea.

Drug Dose ::

 Route/Dosage

ADULT: PO 1 mg/day initially. If after 4 wk the 1 mg/day dose is well tolerated but does not adequately control IBS symptoms, the dose can be increased to 1 mg bid.

Contraindication ::

 Contraindications History of chronic or severe constipation or sequelae from constipation; history of intestinal obstruction, stricture, toxic megacolon, GI perforation, or adhesions; history of ischemic colitis; current or history of Crohn disease or ulcerative colitis; active diverticulitis. Do not initiate therapy in patients with constipation (fewer than 3 bowel movements a week, hard or lumpy stools, or straining during a bowel movement).

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk of lactating rats. CHILDREN: Safety and efficacy not established. ELDERLY: Safety was similar in older and younger patients. GI events: Serious complications of constipation and ischemic colitis may result in hospitalization, blood transfusion, surgery, and death. Hepatic impairment: Increased exposure to alosetron is likely to occur in patients with hepatic insufficiency; use with caution.

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Hypertension. CNS: Sleep disorders; depressive disorders. GI: Constipation; nausea; GI discomfort and pain; abdominal discomfort and pain; GI gaseous symptoms; viral GI infections; dyspeptic symptoms; abdominal distention; hemorrhoids. RESPIRATORY: Allergic rhinitis; throat and tonsil discomfort and pain; bacterial ear, nose and throat infections.

Drug Mode of Action ::  

(al-OH-seh-trahn)

Lotronex

Tablets: 1.124 mg (equivalent to 1 mg alosetron base)

Class: 5HT3 receptor antagonist

Drug Interactions ::

 Interactions None well documented.

Drug Assesment ::

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk of lactating rats. CHILDREN: Safety and efficacy not established. ELDERLY: Safety was similar in older and younger patients. GI events: Serious complications of constipation and ischemic colitis may result in hospitalization, blood transfusion, surgery, and death. Hepatic impairment: Increased exposure to alosetron is likely to occur in patients with hepatic insufficiency; use with caution.

Drug Storage/Management ::

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk of lactating rats. CHILDREN: Safety and efficacy not established. ELDERLY: Safety was similar in older and younger patients. GI events: Serious complications of constipation and ischemic colitis may result in hospitalization, blood transfusion, surgery, and death. Hepatic impairment: Increased exposure to alosetron is likely to occur in patients with hepatic insufficiency; use with caution.

Drug Notes ::

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk of lactating rats. CHILDREN: Safety and efficacy not established. ELDERLY: Safety was similar in older and younger patients. GI events: Serious complications of constipation and ischemic colitis may result in hospitalization, blood transfusion, surgery, and death. Hepatic impairment: Increased exposure to alosetron is likely to occur in patients with hepatic insufficiency; use with caution.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.